A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2002
10/17/2002	US20020151516 Carrier:nucleic acids complexes containing nucleic acids encoding anti-angiogenic peptides and their use in gene therapy
10/17/2002	US20020151514 Genes associated with mechanical stress, expression products therefrom, and uses thereof
10/17/2002	US20020151512 Used to diagnose or treat cancer, restenosis, a disease caused by a virus, a disease affected by integrins or cell-cell adhesion receptor or a disease triggered by diffusible factors
10/17/2002	US20020151508 Administering therapeutically effective amount of liposomal anthracycline composition in association with therapeutically effective amount of antibody directed against extracellular domain of growth factor receptor
10/17/2002	US20020151506 Catechins for the treatment of fibrillogenesis in Alzheimer's disease, Parkinson's disease, systemic AA amyloidosis, and other amyloid disorders
10/17/2002	US20020151505 Treatment of helicobacter with isothiocyanates
10/17/2002	US20020151503 Methods of cancer treatment using naaladase inhibitors
10/17/2002	US20020151500 Administering a therapeutically effective amount of a type-5 selective somatostatin agonist to patient
10/17/2002	US20020151498 Medicaments that modify activity of Lipolysis Stimulated Receptor and that can be used to influence partitioning of dietary lipids between liver and peripheral tissues, including adipose tissue
10/17/2002	US20020151496 Treatment of spinal cord damage, spinal cord trauma, neuronal tissue damage produced by ischemic attack
10/17/2002	US20020151493 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
10/17/2002	US20020151491 Uses MUC5AC plasmid to identify cytoplasmic proteins of Nontypeable Haemophilus influenzae, a mediator of otitis media and chronic obstructive pulmonary disease, which up-regulates human mucin transcription
10/17/2002	US20020151485 Methods and compositions for modulating fertility
10/17/2002	US20020151480 Identifying a compound to treat a cardiovascular disease, e.g., atherosclerosis, characterized by aberrant 10218 nucleic acid activity or expression; detecting the presence of a nucleic acid in the sample that hybridizes to the probe
10/17/2002	US20020151470 Inhibitors of phospholipase A2
10/17/2002	US20020151465 Decrease hyperalgesia, without impairing nociception
10/17/2002	US20020151461 Modified retinoblastoma tumor supressor proteins
10/17/2002	US20020151460 Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
10/17/2002	US20020151459 Methods for identifying compounds useful for inhibiting farnesyl diphosphate synthase
10/17/2002	US20020151088 Rapamycin conjugates
10/17/2002	US20020151049 Self-enhancing, pharmacologically controllable expression systems
10/17/2002	US20020151022 Kinase capable of site-specific phosphorylation of IkappaBalpha
10/17/2002	US20020150986 Extracellular matrix signalling molecules
10/17/2002	US20020150977 Nucleotide sequences coding protein for use in the diagnosis, treatment and prevention of autoimmune, cell proliferative and inflammatory diseases
10/17/2002	US20020150963 Map
10/17/2002	US20020150681 Substrate with a photocatalytic coating
10/17/2002	US20020150653 Food and vitamin preparations containing the natural isomer of reduced folates
10/17/2002	US20020150639 Laxative; solvent extraction of plant; side effect reduction
10/17/2002	US20020150635 Therapy for bacteria infections
10/17/2002	US20020150632 Psychonutracological method for craving reduction in humans
10/17/2002	US20020150631 Methods of treating prion disease in mammals
10/17/2002	US20020150629 Enhancing absorption; mixture of zinc compound and dipeptide
10/17/2002	US20020150628 Microbiocides; viricides; anticancer agents
10/17/2002	US20020150625 Fineness particle size; hormone replacement therapy
10/17/2002	US20020150624 Mixture of drug, aminoacrylate polymer and acid
10/17/2002	US20020150622 Controlled release of anti-arrhythmic agents
10/17/2002	US20020150620 Oral itraconazole formulations and methods of making the same
10/17/2002	US20020150619 Erythromyacin antibiotic product, use and formulation thereof
10/17/2002	US20020150618 Process for preparing solid dosage forms of very low-dose drugs
10/17/2002	US20020150617 Free of excipients; compaction
10/17/2002	US20020150615 Injectable pharmaceutical composition comprising microdroplets of a camptothecin
10/17/2002	US20020150601 Topical applying
10/17/2002	US20020150600 Conjugate, its preparation and use
10/17/2002	US20020150595 Antigenic preparations and the isolation of such preparations
10/17/2002	US20020150591 Amplification nucleic acids
10/17/2002	US20020150565 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/17/2002	US20020150558 Immobilization; viricides
10/17/2002	US20020150554 Chicken interleukin-15 and uses thereof
10/17/2002	US20020150550 Cosmetic surgery
10/17/2002	US20020150549 Sustained release
10/17/2002	US20020150542 Concentrate blend; fine spray; miniaturized container
10/17/2002	US20020150538 Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
10/17/2002	US20020150534 Tumor necrosis factor-gamma
10/17/2002	US20020148463 Use of intracellular calcium chelators to increase surfactant secretion in the lungs
10/17/2002	US20020148281 Single riser/single capillary blood viscometer using mass detection or colum height detection
10/17/2002	DE10201458A1 New proteins involved in isoprenoid biosynthesis, useful in screening for inhibitors, also new intermediates, potential therapeutic agents, nucleic acids and antibodies
10/17/2002	DE10164711A1 Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren und/oder Aminosäureanalogen zur Modulation des Glycolyse-Enzym-Komplexes, des Malat Aspartat Shuttles und/oder der Transaminasen Use of sugar phosphates, sugar phosphate analogs, amino acids and / or amino acid analogs to modulate the glycolytic enzyme complex, the malate aspartate shuttle and / or the transaminases
10/17/2002	DE10155685A1 Preparation of controlled release tablets containing the calcium channel blocker nimodipine in amorphous form, useful e.g. in treating cerebral diseases, under mild temperature conditions to give good release profile
10/17/2002	DE10134768A1 Pharmazeutische Kombinationspräparate enthaltend Aromatasehemmer und Substanzen mit estrogener Wirkung sowie ihre Verwendung Pharmaceutical combination preparations containing aromatase inhibitors and substances with estrogenic effects and their use
10/17/2002	DE10130819A1 Low-toxicity intravenous immunosuppressive medicament comprising fusidic acid, useful for suppressing graft-versus-host reactions and treating environmental diseases such as occupational dermatosis
10/17/2002	DE10118551A1 New 2-aza-bicyclo (2.2.1) heptane derivatives, are nicotinic acetyl choline receptor ligands useful for e.g. treating schizophrenia, depression or neurodegenerative diseases
10/17/2002	DE10118550A1 New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections
10/17/2002	DE10118306A1 Composition for intranasal administration of imidazo-triazinone derivative cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
10/17/2002	DE10118305A1 Composition for intranasal administration of cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
10/17/2002	DE10118146A1 Artificial respiration apparatus, for patients with a respiratory distress syndrome, has an aerosol generator at the hose system to give an effective delivery of perfluorocarbon into the patient's lungs
10/17/2002	DE10118070A1 Potent, long-lasting analgesic composition with no significant side-effects, containing diclofenac sodium, coffee, ignatia, nutmeg, valerian and zinc valerate
10/17/2002	DE10117834A1 Zytoprotektion durch Phosphotyrosin Cytoprotection by phosphotyrosine
10/17/2002	DE10117728A1 Pharmazeutische Formulierungen für Xanthogenate Pharmaceutical formulations for xanthates
10/17/2002	DE10117184A1 Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen Substituted imidazol [1,2-a] pyridin-3-yl-amide, and amine compounds of
10/17/2002	DE10116527A1 Tumorhemmende Galliumverbindungen Tumor-inhibiting gallium
10/17/2002	DE10116197A1 New lipid-soluble methylprednisolone 21-ester derivatives, useful as antiinflammatory, immunosuppressive or antiallergic agents, especially in liposome formulations or lipid coatings on implants
10/17/2002	CA2719162A1 Methods of treating acne
10/17/2002	CA2699611A1 Desaturase genes and uses thereof
10/17/2002	CA2698579A1 Desaturase genes and uses thereof
10/17/2002	CA2457443A1 Composition and method for the treatment of respiratory disease
10/17/2002	CA2446886A1 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
10/17/2002	CA2444024A1 Thiohydantoins and use thereof for treating diabetes
10/17/2002	CA2443813A1 Method for identification of proteins from intracellular bacteria
10/17/2002	CA2443405A1 Use of cd25 binding molecules in steroid-resistant patients
10/17/2002	CA2443372A1 Immunotherapeutic combinations for the treatment of tumors that over-express gangliosides
10/17/2002	CA2443362A1 Stabilization and terminal sterilization of phospholipid formulations
10/17/2002	CA2443323A1 Nucleic acid vaccines for prevention of flavivirus infection
10/17/2002	CA2443275A1 Improved gene expression
10/17/2002	CA2443108A1 N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
10/17/2002	CA2443099A1 Uses of benzylideneamino guanidines as ligands to the melanocortiin receptors
10/17/2002	CA2443092A1 Use of n-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders
10/17/2002	CA2443057A1 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
10/17/2002	CA2443042A1 Novel use of arylethene sulfonamide derivatives
10/17/2002	CA2443040A1 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenyl-sulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
10/17/2002	CA2443031A1 Use of selective cox-2 inhibitors for the treatment of urinary incontinence
10/17/2002	CA2443018A1 Papaine containing pharmaceutical formulation resp. its use
10/17/2002	CA2443015A1 Aryl (or heteroaryl) azolylcarbinole derivatives for the treatment of respiratory diseases
10/17/2002	CA2442996A1 Use of substituted imidazo[1,2-a]-pyridine compounds as medicaments
10/17/2002	CA2442991A1 Compositions and methods for the prevention and treatment of human prostate cancer
10/17/2002	CA2442986A1 Use of substituted imidazo[1,2-a]-pyridine-3-yl-amide and imidazo[1,2-a]-pyridine-3-yl-amine compounds as medicaments
10/17/2002	CA2442923A1 Polysubstituted polycarboxylic phosphoamide biopolymers, methods for their production and uses of compositions derived therefrom
10/17/2002	CA2442904A1 Benzamidine derivative
10/17/2002	CA2442863A1 Tumour inhibiting gallium compounds
10/17/2002	CA2442858A1 Zinc ionophores as anti-stress agents
10/17/2002	CA2442849A1 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil

1 ... 5678 5679 5680 5681 5682 5683 5684 5685 5686 5687 5688 5689 5690 5691 5692 5693 5694 5695 5696 5697 5698 ... 7860